Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report) traded up 104.5% during trading on Monday . The company traded as high as $4.50 and last traded at $4.50. Approximately 700 shares were traded during mid-day trading, a decline of 67% from the average daily volume of 2,112 shares. The stock had previously closed at $2.20.
Silence Therapeutics Stock Performance
The business has a 50-day moving average price of $1.73 and a 200 day moving average price of $1.79.
Silence Therapeutics Company Profile
Silence Therapeutics is a clinical-stage biotechnology company focused on the development of small interfering RNA (siRNA) therapies designed to silence disease-causing genes. The company’s proprietary AtuRNAi platform employs ligand-conjugated siRNA to enable targeted delivery and extended duration of action, with the aim of addressing chronic and severe diseases. Silence Therapeutics advances its own pipeline programs while also forming strategic partnerships to leverage its delivery technology in indications such as cardiovascular disease, metabolic disorders and rare genetic conditions.
The company’s lead program, SLN360, is designed to reduce lipoprotein(a), a known independent risk factor for cardiovascular events, and is currently in clinical development.
Featured Stories
- Five stocks we like better than Silence Therapeutics
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
